• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Clinical efficacy and safety of flumatinib combined with multidrug chemotherapy in the treatment of 12 cases with Ph(+) acute lymphoblastic leukemia].

作者信息

Mi R H, Chen L, Yang H P, Wei X L, Liu J, Yin Q S, Zhang L N, Wei X D

机构信息

The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou 450008, China.

The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):858-861. doi: 10.3760/cma.j.issn.0253-2727.2021.10.011.

DOI:10.3760/cma.j.issn.0253-2727.2021.10.011
PMID:34788927
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8607012/
Abstract
摘要

相似文献

1
[Clinical efficacy and safety of flumatinib combined with multidrug chemotherapy in the treatment of 12 cases with Ph(+) acute lymphoblastic leukemia].氟马替尼联合多药化疗治疗12例Ph(+)急性淋巴细胞白血病的临床疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):858-861. doi: 10.3760/cma.j.issn.0253-2727.2021.10.011.
2
[Clinical observation of flumatinib combined with induction chemotherapy and sequential allogeneic hematopoietic stem cell transplantation in the treatment of 6 patients with newly diagnosed Ph(+) acute lymphocytic leukemia].氟马替尼联合诱导化疗及序贯异基因造血干细胞移植治疗6例初诊Ph(+)急性淋巴细胞白血病的临床观察
Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):169-172. doi: 10.3760/cma.j.issn.0253-2727.2023.02.017.
3
Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia.西达本胺联合化疗治疗难治/复发 T 淋巴母细胞淋巴瘤/白血病。
Leuk Lymphoma. 2020 Apr;61(4):855-861. doi: 10.1080/10428194.2019.1691195. Epub 2019 Nov 22.
4
Time to tune the treatment of Ph+ ALL.调整 Ph+ ALL 治疗方案的时机。
Blood. 2015 Jun 11;125(24):3674-5. doi: 10.1182/blood-2015-04-641704.
5
Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation.氟马替尼治疗初诊慢性髓性白血病慢性期的疗效和安全性：一项真实世界的单中心回顾性研究，重点关注提前停药。
Leuk Res. 2024 Jul;142:107507. doi: 10.1016/j.leukres.2024.107507. Epub 2024 Apr 26.
6
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.Ph 阳性急性淋巴细胞白血病成人患者中采用减低强度化疗联合伊马替尼的随机研究。
Blood. 2015 Jun 11;125(24):3711-9. doi: 10.1182/blood-2015-02-627935. Epub 2015 Apr 15.
7
Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage.低剂量地西他滨增强西达本胺诱导的成人急性淋巴细胞白血病细胞凋亡，尤其通过DNA损伤对p16缺失患者作用明显。
Pharmacogenomics. 2017 Aug;18(13):1259-1270. doi: 10.2217/pgs-2017-0061. Epub 2017 Jul 26.
8
[Clinical study of 32 patients with adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Dec;22(6):1567-71. doi: 10.7534/j.issn.1009-2137.2014.06.013.
9
[Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].[儿童高危急性淋巴细胞白血病的治疗策略]
Beijing Da Xue Xue Bao Yi Xue Ban. 2013 Apr 18;45(2):327-32.
10
Simultaneous determination of flumatinib and its two major metabolites in plasma of chronic myelogenous leukemia patients by liquid chromatography-tandem mass spectrometry.采用液相色谱-串联质谱法同时测定慢性髓性白血病患者血浆中的氟马替尼及其两种主要代谢物。
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 May 1;895-896:25-30. doi: 10.1016/j.jchromb.2012.03.008. Epub 2012 Mar 15.

引用本文的文献

1
[Advances in basic and clinical research of flumatinib].氟马替尼的基础与临床研究进展
Zhonghua Xue Ye Xue Za Zhi. 2024 Jun 14;45(6):621-624. doi: 10.3760/cma.j.cn121090-20231211-00304.
2
Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin's therapeutic potential.克服慢性髓性白血病中的 flumatinib 耐药性：对细胞机制和伊维菌素治疗潜力的深入了解。
J Cell Mol Med. 2024 Jul;28(14):e18539. doi: 10.1111/jcmm.18539.
3
Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.氟马替尼与达沙替尼联合多药化疗治疗成人费城染色体阳性急性淋巴细胞白血病的临床疗效与安全性
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S71-S78. doi: 10.1016/j.htct.2023.12.005. Epub 2024 Feb 20.

本文引用的文献

1
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study.氟马替尼与伊马替尼治疗新诊断的慢性期慢性髓性白血病：一项III期、随机、开放标签、多中心FESTnd研究。
Clin Cancer Res. 2021 Jan 1;27(1):70-77. doi: 10.1158/1078-0432.CCR-20-1600. Epub 2020 Sep 14.
2
Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants.基于结构的分析和伊马替尼衍生物的生物学特性研究揭示了抑制野生型 BCR-ABL 及其突变体的新见解。
Bioorg Med Chem Lett. 2019 Dec 15;29(24):126758. doi: 10.1016/j.bmcl.2019.126758. Epub 2019 Oct 28.
3
Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up.尼罗替尼联合多药物化疗治疗初诊费城染色体阳性急性淋巴细胞白血病：一项单中心前瞻性研究及长期随访。
Ann Hematol. 2019 Mar;98(3):633-645. doi: 10.1007/s00277-019-03594-1. Epub 2019 Jan 11.
4
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.Ponatinib 对比早期一代酪氨酸激酶抑制剂用于新诊断费城阳性急性淋巴细胞白血病一线治疗的疗效。
Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):257-265. doi: 10.1016/j.clml.2018.02.010. Epub 2018 Feb 17.
5
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.成人Ph+急性淋巴细胞白血病采用伊马替尼、化疗和移植的序贯治疗方法：GIMEMA LAL 0904研究的最终结果
Haematologica. 2016 Dec;101(12):1544-1552. doi: 10.3324/haematol.2016.144535. Epub 2016 Aug 11.
6
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.一项关于化疗联合达沙替尼用于初治费城染色体阳性急性淋巴细胞白血病患者的2期研究的长期随访
Cancer. 2015 Dec 1;121(23):4158-64. doi: 10.1002/cncr.29646. Epub 2015 Aug 26.
7
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.甲磺酸伊马替尼联合hyper-CVAD一线治疗成人费城染色体阳性急性淋巴细胞白血病的II期研究最终报告
Haematologica. 2015 May;100(5):653-61. doi: 10.3324/haematol.2014.118588. Epub 2015 Feb 14.
8
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance.HH-GV-678，一种新型的Bcr-Abl选择性抑制剂，其性能优于伊马替尼，并能有效克服伊马替尼耐药性。
Leukemia. 2010 Oct;24(10):1807-9. doi: 10.1038/leu.2010.169. Epub 2010 Aug 12.
9
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.关于267例未经选择的费城染色体阳性成人急性淋巴细胞白血病患者的前瞻性结局数据证实，在伊马替尼时代之前，异基因移植优于化疗：来自国际ALL试验MRC UKALLXII/ECOG2993的结果。
Blood. 2009 May 7;113(19):4489-96. doi: 10.1182/blood-2009-01-199380. Epub 2009 Feb 24.
10
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.达沙替尼可使对伊马替尼耐药或不耐受的费城染色体阳性成人急性淋巴细胞白血病患者迅速获得血液学和细胞遗传学缓解：一项2期研究的中期结果。
Blood. 2007 Oct 1;110(7):2309-15. doi: 10.1182/blood-2007-02-073528. Epub 2007 May 11.